DELIVER at ESC Congress 2023

The DELIVER team was proud to present at ESC Congress 2023 in Amsterdam, Netherlands. The following analyses were presented:

• Effects of Dapagliflozin in Patients with Heart Failure and Deterioration of Kidney Function Below eGFR 25ml/min/1.73m^2 presented by Scott Solomon

• Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial presented by Safia Chatur

• Influence of background therapy on efficacy of dapagliflozin in patients with heart failure and improved ejection fraction presented by Maria Pabon

• Effects of dapagliflozin in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease: an analysis of the DELIVER trial presented by Jawad Haider Butt

• Effect of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction treated with beta-blockers: the DELIVER trial presented by Alexander Peikert

• Effect of dapagliflozin in patients in Asia with heart failure with mildly reduced or preserved ejection fraction: insights from DELIVER presented by Xiaowen Wang

• Efficacy of dapagliflozin according to geographic regions in patients with heart failure: a patient-level pooled analysis of DAPA-HF and DELIVER presented by Toru Kondo